scholarly journals Racial Variation in Serum Lipid and Lipoprotein Levels in Type 2 Diabetic Subjects of Bangladesh

1970 ◽  
Vol 17 ◽  
pp. 113-116 ◽  
Author(s):  
Mohammad Razuanul Hoque ◽  
Md Golam Kabir ◽  
Dwaipayan Sikdar
Keyword(s):  
Total Cholesterol ◽  
Racial Differences ◽  
Serum Lipid ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Atherogenic Index ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Context: Racial and sex differences are documented globally regarding patterns of serum lipids among diabetic patients. Differences of lipid profile of normal and diabetic subjects of the different ethnic groups of Bangladesh may differ.Objectives: To find out if there were any differences in the serum lipid and lipoprotein levels in the type 2 diabetic patients of two different races namely, Bangalee and Chakma of Bangladesh. Materials and Methods: Study population consisted of 76 (Chakma / Bangalee: 35 / 41) patients aged between 40-60 years with type 2 diabetes mellitus who were on follow-up at the Rangamati Diabetes Hospital, Chittagong Hill Tract, Bangladesh and forty (Chakma / Bangalee: 20 / 20) non-diabetic subjects of same age were randomly selected as control. Biochemical parameters analyzed include - Serum total cholesterol and triglyceride (TG), serum high-density lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol and atherogenic index.Results:  Dyslipidemia was found in the diabetic patients of both races and the patients had higher serum TG), atherogenic index and lower serum HDL than their normal counterpart. The Bangalee patients were found to have higher TG and lower atherogenic index compared with the Chakma patients although no racial differences found regarding total, HDL and LDL cholesterol. Also no differences were found between the lipid profiles of normal control subjects of these two races. Conclusion: Present study confirms that racial differences exist in serum lipid abnormalities between Chakma and Bangalee subjects with type 2 diabetes.Key words: Diabetes Type 2; Triglyceride; Lipoprotein; Total cholesterol; Bangalee; Chakma.DOI: 10.3329/jbs.v17i0.7116J. bio-sci. 17: 113-116, 2009

Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients

2010 ◽  
Vol 118 (10) ◽  
pp. 607-615 ◽  
Author(s):  
Sandra J. Hamilton ◽  
Gerard T. Chew ◽  
Timothy M.E. Davis ◽  
Gerald F. Watts
Keyword(s):  
Endothelial Dysfunction ◽  
Endothelial Function ◽  
Statin Therapy ◽  
Brachial Artery ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Dyslipidaemia contributes to endothelial dysfunction and CVD (cardiovascular disease) in Type 2 diabetes mellitus. While statin therapy reduces CVD in these patients, residual risk remains high. Fenofibrate corrects atherogenic dyslipidaemia, but it is unclear whether adding fenofibrate to statin therapy lowers CVD risk. We investigated whether fenofibrate improves endothelial dysfunction in statin-treated Type 2 diabetic patients. In a cross-over study, 15 statin-treated Type 2 diabetic patients, with LDL (low-density lipoprotein)-cholesterol <2.6 mmol/l and endothelial dysfunction [brachial artery FMD (flow-mediated dilatation) <6.0%] were randomized, double-blind, to fenofibrate 145 mg/day or matching placebo for 12 weeks, with 4 weeks washout between treatment periods. Brachial artery FMD and endothelium-independent NMD (nitrate-mediated dilatation) were measured by ultrasonography at the start and end of each treatment period. PIFBF (post-ischaemic forearm blood flow), a measure of microcirculatory endothelial function, and serum lipids, lipoproteins and apo (apolipoprotein) concentrations were also measured. Compared with placebo, fenofibrate increased FMD (mean absolute 2.1±0.6 compared with −0.3±0.6%, P=0.04), but did not alter NMD (P=0.75). Fenofibrate also increased maximal PIFBF {median 3.5 [IQR (interquartile range) 5.8] compared with 0.3 (2.1) ml/100 ml/min, P=0.001} and flow debt repayment [median 1.0 (IQR 3.5) compared with −1.5 (3.0) ml/100 ml, P=0.01]. Fenofibrate lowered serum cholesterol, triacylgycerols (triglycerides), LDL-cholesterol, apoB-100 and apoC-III (P≤0.03), but did not alter HDL (high-density lipoprotein)-cholesterol or apoA-I. Improvement in FMD was inversely associated with on-treatment LDL-cholesterol (r=−0.61, P=0.02) and apoB-100 (r=−0.54, P=0.04) concentrations. Fenofibrate improves endothelial dysfunction in statin-treated Type 2 diabetic patients. This may relate partly to enhanced reduction in LDL-cholesterol and apoB-100 concentrations.

scholarly journals Evaluation of lipid profile pattern and atherogenic index of plasma (AIP) having type-2 diabetes mellitus in Bangladesh

2018 ◽  
Vol 6 (3) ◽  
pp. 776
Author(s):  
Mahfuza Anjum ◽  
Md. Salah Uddin ◽  
Naima Ahmed Tamanna ◽  
Md. Abdullah Al-Zobair ◽  
A. T. M. Mijanur Rahman
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Density Lipoprotein ◽  
Atherogenic Index ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Atherogenic Index Of Plasma ◽  
Type 2 Diabetic

Background: Dyslipidemia has been noted to play an integral role in the pathogenesis and progression of micro and macrovascular complications in Diabetes Mellitus (DM) patients. The study was aimed to evaluate the prevalence and pattern of dyslipidemia and atherogenic index of plasma (AIP) in type 2 diabetes mellitus patients as it has not been reported previously in BangladeshMethods: This cross-sectional study was conducted at Armed Forces Institute of pathology, Bangladesh from November 2016 to October 2017. A total number of 300 patients having diabetes in the age group of 30-60 years have been selected using a non-probability method. Fasting plasma glucose (FPG), serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels were estimated by laboratory tests.Results: The prevalence of dyslipidemia in at least one lipid parameter was found in 282 patients (94%), while 18 patients (6%) had no dyslipidemia. High levels of TC, TG and LDL-C were found in 134 (47.3%), 230 (76.7%) and 124 (41.3%) patients, respectively. On the other hand, low levels of HDL-C were found in 180 patients (60%). An increased risk of AIP was found in 298 patients (99.3%), whereas only 2 patients (0.7%) were in low risk. FPG was positively correlated with TC, TG, LDL-C and AIP, while negatively correlated with HDL-C. A significant positive correlation was also observed between FPG and AIP.Conclusions: The Study revealed that dyslipidemia is very common in type 2 diabetic patients and the most common abnormality observed was increased serum triglyceride levels followed by decreased serum HDL-C levels. The AIP is also significantly higher in type 2 diabetic patients.

scholarly journals Study of Correlation Between Glycated Hemoglobin (Hba1c) and Serum Lipid Profile in Type 2 Diabetic Patients

2020 ◽  
Vol 18 (1) ◽  
pp. 67-69
Author(s):  
Anil Shrestha
Keyword(s):  
Lipid Profile ◽  
Serum Lipid ◽  
Glycated Hemoglobin ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Low Density ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Introduction: Diabetic mellitus is a chronic metabolic disease characterized by hyperglycemia. Type 2 diabetes mellitus accounts for more than 90% of cases worldwide. Elevated HbA1c and dyslipidemia proportionately increases the risk of development of cardiovascular disease (CVD) which is the major cause of morbidity and mortality worldwide. Aims: To Study the correlation between glycated hemoglobin (HbA1c) and serum lipid profile in type 2 diabetic patients. Methods: This is a hospital based cross sectional study conducted at Nepalgunj medical college teaching hospital, which included 104 type 2 diabetic patients (54 males and 50 females).Venous blood samples were collected from all patients and serum was used for analyzing HbA1c, lipid profile panel and fasting blood glucose (FBG). DM was defined as per American diabetic association (ADA) criteria. Dyslipidemia was defined as per the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Guidelines. The data were analyzed using standard statistical methods, including SPSS 21. Results : Abnormal lipid parameters were demonstrated with increased Total Chloseterol (TC), Triglyceride (TG), Low density lipoprotein (LDL),Very low density lipoprotein (VLDL) and low High density lipoprotein (HDL)  suggestive of dyslipidemia.HbA1c showed direct and significant correlation with TC,LDL,TG and VLDL. Patients with HbA1c  > 7.0% had a significantly higher value of TC, LDL, TG and VLDL as compared to patients with HbA1c ≤7.0%.However, the significant difference in value of HDL-C was not found between two groups. Conclusion: Due to the strong correlation with lipid profile, HbA1c could be the ideal marker for predicting dyslipidemia in type 2 DM . Patients with higher HbA1c value and dyslipidemia should be considered as a very high risk group for CVD.

scholarly journals Lipid Profile of Type 2 Diabetic and Hypertensive Patients in the Jamaican Population

2010 ◽  
Vol 2 (01) ◽  
pp. 025-030 ◽  
Author(s):  
Lorenzo Gordon ◽  
Dalip Ragoobirsingh ◽  
Errol Y St A Morrison ◽  
Eric Choo-Kang ◽  
Donovan McGrowder ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Diabetic Patients ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Type 2 Diabetic Patients ◽  
Type 2 Dm ◽  
Type 2 Diabetic

ABSTRACT Aims: Previous studies have shown that diabetes mellitus (DM) increases the risk of cardiovascular diseases in females to a greater extent than in males. In this cross-sectional study, we evaluated the lipid profiles of type 2 diabetic males and females. Materials and Methods: The study included 107 type 2 diabetic patients (41 males and 66 females), and 122 hypertensive type 2 diabetic patients (39 males and 83 females), aged 15 years and older. Total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C), very low density lipoprotein-cholesterol (VLDL-C) and high density lipoprotein-cholesterol (HDL-C) concentrations were assayed for each group using standard biochemical methods. Results: The mean TC, TG, VLDL-C, HDL-C and LDL-C concentrations, TG/HDL and LDL/HDL ratios were higher in type 2 diabetic and hypertensive type 2 diabetic patients compared with non-diabetic, and hypertensive non-diabetic control subjects, although these were not significant (P > 0.05). Hypertensive type 2 diabetic females had significantly higher serum TC (7.42 ± 1.63 mmol/L) than hypertensive non-diabetic males (5.76±1.57 mmol/L; P < 0.05). All the other lipid and lipoprotein parameters except HDL-C were non-significantly higher in females with type 2 DM and those with hypertension and type 2 DM, compared with type 2 diabetic and hypertensive type 2 diabetic males, respectively (P > 0.05). Conclusion: This study demonstrated that dyslipidemia exists in our type 2 diabetic population with greater TC in hypertensive type 2 diabetic females compared with hypertensive type 2 diabetic males. This suggests that hypertensive type 2 diabetic females are exposed more profoundly to risk factors including atherogenic dyslipidemia compared with males.

scholarly journals Effect of atorvastatin on oxidative stress parameters and lipid profile in type 2 diabetic patients

2020 ◽  
Vol 7 (2) ◽  
Author(s):  
Najah RH ◽  
Mohammad AAH ◽  
Ammar RMR
Keyword(s):  
Oxidative Stress ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Oxidative Stress Parameters ◽  
Type 2 Diabetic ◽  
Stress Parameters

Introduction: Evidence has long existed regarding the relationship between oxidative stress and diabetes. The present study was conducted to assess the effect of atorvastatin on selected oxidative stress parameters in the form of reduced glutathione (GSH), lipid peroxidation byproduct malondialdehyde (MDA) levels, glutathione –S- transferase (GST) activity and catalase (CAT) activity) and its effect on lipid profile (total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) in dyslipidaemic type 2 diabetic patients . Materials and Methods: Fifty nine dyslipidaemic type 2 diabetic patients were included in this study. Full history was taken and general examination of patients was performed. Patients studied were taking glibenclamide (an oral hypoglycaemic drug) during the study as a treatment for their disease. These patients were followed up for 60 days and divided randomly into 2 groups. Group I (n = 31): no drug was given and served as dyslipidaemic diabetic control. Group II (n = 28): received atorvastatin tablets 20 mg once daily at night. Of the 59 Fifty patients, 46 completed the study while 13 patients withdrew. This is due to non compliance of the patients. Blood samples were drawn from the patients at the beginning and after 60 days of follow up between 8:30 & 10:30 am after at least 12-14 hours fast. Fasting blood glucose, lipid profile, selected oxidative stress parameters (GSH, MDA levels, GST and CAT activities) were measured. Renal and hepatic functions were also assessed. Results: This study revealed that: atorvastatin treatment increased serum GSH; reduced MDA levels significantly while did not significantly affect CAT and GST activity. In atorvastatin treatment, TC, TG, LDL and VLDL decreased significantly while HDL increased significantly. Conclusion: There was insignificant correlations between atorvastatin induced changes in the oxidation markers and the observed changes of the lipid profile.

Inverse Association of Serum Fibroblast Growth Factor 19 and Atherogenic Index of Plasma in Type 2 Diabetic Patients

2020 ◽  
Author(s):  
Wangshu Liu ◽  
Tianli Xu ◽  
Mengjie Tang ◽  
Xue-Qin Wang ◽  
Jianbin Su ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Atherogenic Index ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Type 2 Diabetic Patients ◽  
Atherogenic Index Of Plasma ◽  
Fibroblast Growth Factor 19 ◽  
Type 2 Diabetic

Abstract BackgroundWe aimed to explore the relationship between serum fibroblast growth factor 19 (FGF19) and the atherogenic index of plasma (AIP) in type 2 diabetic patients.MethodsSerum FGF19 levels and lipid profiles were measured in 200 patients with type 2 diabetes (T2D). The levels of serum FGF19 were measured by ELISA. Lipid profiles were measured by enzymatic analysis. AIP and NAFLD fibrosis scores were calculated.ResultsT2D patients showed a significant decreasing trend of FGF19 concentrations depending on the tertiles of AIP (p for trend < 0.05). Simultaneously, the AIP level was closely related to the serum FGF19 level (p < 0.05). Furthermore, after adjusting for age, sex, duration, BMI, hypertension, and diabetic treatment, the correlation was still significant (p < 0.01), and it remained significant even after further adjusting for non-alcoholic fatty liver disease (NAFLD) and NAFLD fibrosis score (NFS) (p < 0.01). However, when stratified by BMI, AIP was positively correlated with FGF19 in normal-weight and overweight T2D patients but not in obese T2D subjects. After adjusting for sex, age, BMI, duration, hypertension, HbA1c, 2hPG, HOMA-IR, AIP, antidiabetic treatments, NAFLD and NFS via multiple stepwise linear regression, AIP was an independent factor affecting serum FGF19 concentrations (SE = 0.238, β = -0.290, p < 0.01).ConclusionsSerum FGF19 levels might be a good predictor for atherosclerosis and cardiovascular disease in T2D patients, especially among non-obese patients; serum FGF19 levels were significantly inversely associated with AIP.

Sign in / Sign up

Export Citation Format

Share Document